Glytrix Inc has developed a platform technology for tissue healing and regeneration. The lead product of Glytrixâs platform is Pelladerm, a therapeutic for preventing scarring of the skin. There is currently no standard of treatment for dermal scarring. There are several homeopathic and over-the-counter remedies available directly to the consumer, which advertise reduction in scar appearance after use over several weeks or months. None of these products prevent the formation of the scar, but are rather marketed to reduce the appearance of scars already formed. Pelladerm is the lead product in Glytrixâs platform technology, designed to improve adult tissue healing and regeneration. The technology is a novel class of molecules called peptidoglycans, which are derived from natural tissue components and engineered for target applications. Glytrixâs peptidoglycan therapeutics are a unique approach to healing in that they aim to restore a healthy tissue environment to promote proper healing, setting Glytrix apart from the competition primarily focused on directly targeting cells and cell function. It is well known that the tissue environment affects cellular behavior and the resulting healing response. Glytrixâs technology works to restore a healthy tissue environment, which promotes efficient and effective healing, significantly preventing and reducing scar tissue formation. Pelladerm is designed to fit within current surgical practices and with the surgeonâs ease of use in mind. The product is a sterile solution, which is easily applied as single dose treatment at the time of injury, followed by standard of care for wounds. This method of use does not require any changes to current wound care practices, while offering superior cosmetic outcome. Cost efficient production of Pelladerm makes its use feasible as either an optional or built in procedural cost. It is anticipated that Pelladerm will substantially improve clinical outcomes and will change the current expectations of scar formation in general and cosmetic surgeries as well as in treatment of trauma and burn injuries. The ease of use without changing standard of care for wounds, coupled with strong efficacy in preventing dermal scarring, position Pelladerm well for the first product of its kind and warrant further development for FDA
